Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Orchard Therapeutics plc (the “Company”) on Form 10-Q for the period ending September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers does hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
Date: November 14, 2022 | By: | /s/ Bobby Gaspar |
|
| Bobby Gaspar |
|
| Chief Executive Officer (Principal Executive Officer) |
Date: November 14, 2022 | By: | /s/ Frank E. Thomas |
|
| Frank E. Thomas |
|
| President and Chief Operating Officer (Principal Financial Officer and Principal Accounting Officer) |